Amgen Inc. v. Hospira, Inc.
1:20-cv-00201
Overview
Parties
Defendant
Hospira, Inc. Operating Company
Represented By
11 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Heyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Plaintiff
Amgen Manufacturing, Limited NPE (University / Research)
Represented By
14 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Amgen Inc. Operating Company
Represented By
14 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Counter Claimant
Pfizer Inc. Operating Company
Represented By
11 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Heyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 8,273,707 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 54,058,704 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,781,395 B2 | US Continuation / Sibling | View Official Patent → |
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8273707
Process for purifying proteins
|
Filed: 2010-06-23
Issued: 2012-09-25
|
Expired (Term Ended)
Expires: 2024-09-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
53
Dispositive
28
Granted
1
Denied
1
Pending / Review
38
Motions by Category
Key Dispositive Motions & Rulings